GoodRx and Kroger Sign Direct Contracting Agreement
15 5월 2024 - 7:00PM
Business Wire
Companies now offering almost 50% more savings
on most generics at more than 2,200 Kroger Family of Pharmacies
GoodRx (Nasdaq: GDRX), the leading destination for prescription
savings in the U.S., today announced a new direct contracting
agreement with The Kroger Co. to deliver improved prescription
pricing at more than 2,200 Kroger family pharmacy locations
nationwide.
“We are excited to renew our relationship with Kroger,” said
Scott Wagner, Interim CEO of GoodRx. “Kroger has been a valuable
participant in the GoodRx marketplace over the years and an
innovator in healthcare, nutrition and wellness. We’ve leveraged
our direct contracting model to reach an agreement that we believe
supports Kroger’s business goals and helps patients get the
prescriptions they need at affordable prices.”
A key focus for GoodRx in recent years has been transforming how
it delivers value to retail pharmacies. By leveraging its
direct-contracting model, GoodRx and Kroger have reached a mutually
beneficial agreement that enables them to deliver lower prices
directly to patients.
Starting June 1, 2024, patients can present a GoodRx coupon at
Kroger Family of Pharmacies to receive almost 50% more savings on
the expected patient price for most generics, compared to
previously available prices on their prescription medications.
GoodRx will be discussing this news during its Investor Day
today, Wednesday, May 15, starting at 9 a.m. ET. You can register
for the event here.
About GoodRx
GoodRx is the leading destination for prescription savings in
the U.S. We offer consumers free access to transparent and lower
prices for generic and brand medications, as well as comprehensive
healthcare research and information. We also equip healthcare
professionals with efficient ways to find and prescribe affordable
medications. Since 2011, GoodRx has helped consumers save more than
$75 billion and is one of the most downloaded medical apps over the
past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings; the benefits and value of
GoodRx offerings to consumers, Kroger and GoodRx; GoodRx’s direct
contracting approach; and GoodRx’s plans, expectations and
objectives. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause GoodRx’s actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to,
risks relating to GoodRx’s ability to achieve broad market
education and change consumer purchasing habits, changes in
medication pricing and pricing structures, GoodRx’s reliance on a
limited number of industry participants, the competitive nature of
GoodRx’s industry, and the important factors discussed in the
section entitled “Risk Factors” in GoodRx’s Annual Report on Form
10-K for the year ended December 31, 2023, and GoodRx’s other
filings with the Securities and Exchange Commission. These factors
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent GoodRx
management’s estimates as of the date of this press release. While
GoodRx may elect to update such forward-looking statements at some
point in the future, GoodRx disclaims any obligation to do so, even
if subsequent events cause GoodRx’s views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515290020/en/
Media Contact press@goodrx.com
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024